The federal government’s April 2026 partial rescheduling of marijuana—placing FDA-approved products and marijuana subject to a qualifying state-issued medical marijuana license into Schedule III while leaving most adult-use marijuana in Schedule I—has created new conformity pressures for mature medical cannabis states.¹ South Dakota illustrates one variant of this federalism challenge. Unlike states with a single cannabis regulator, South Dakota maintains a classic dual-chapter structure: a comprehensive controlled-substances regime in SDCL Chapter 34-20B and a separate voter-initiated medical cannabis program in SDCL Chapter 34-20G.²
Within this architecture, the South Dakota Board of Pharmacy occupies a distinct, secondary, and primarily implementational role. It is not the primary scheduling authority. That responsibility lies with the Department of Health (DOH), which makes recommendations to the Legislature. The Board’s authority centers on pharmacy practice, controlled-substance handling by licensed pharmacists and pharmacies, inspections, and administrative rulemaking to support whatever statutory schedules the Legislature adopts.³
I. Statutory Architecture: Separate Chapters, Distinct Roles
South Dakota’s controlled-substances law follows the Uniform Controlled Substances Act model. SDCL Chapter 34-20B vests scheduling authority in the DOH. Under SDCL § 34-20B-11 et seq., the Department evaluates substances according to statutory criteria (potential for abuse, accepted medical use, safety) and recommends additions, deletions, or rescheduling to the Legislature.⁴ Marijuana and tetrahydrocannabinol derivatives remain explicitly listed in Schedule I under § 34-20B-14, subject only to narrow statutory carve-outs for industrial hemp, certain FDA-approved products, and the medical cannabis program.⁵
Scheduling changes are not automatic upon federal action. Legislative or formal DOH action is required. This deliberate process explains the methodical, thoughtful, and slower timelines often associated with South Dakota controlled-substances updates.⁶
By contrast, the medical cannabis program operates under the separate Chapter 34-20G. Enacted by voter initiative and administered by the DOH, this chapter creates a comprehensive licensing, registry, and immunity framework for qualifying patients, caregivers, and medical cannabis establishments. It functions as a targeted carve-out from many Chapter 34-20B prohibitions.⁷ Because South Dakota’s medical program issues qualifying state licenses, products distributed under it qualify for the federal partial Schedule III treatment announced in April 2026.⁸
II. The Board of Pharmacy’s Limited but Critical Role
The Board of Pharmacy, governed by SDCL Chapter 36-11, exercises authority over the practice of pharmacy, licensing of pharmacists and pharmacies, and the manner in which controlled substances are dispensed, inventoried, recorded, and secured.⁹ Its powers include:
• Promulgating rules on pharmacy operations involving controlled substances (ARSD Title 20:51 and 44:58), including inventory requirements upon change of pharmacist-in-charge, labeling, partial fills, refills, and security.¹⁰
• Conducting inspections and participating in DEA audits of pharmacies.¹¹
• Overseeing aspects of the Prescription Drug Monitoring Program (PDMP), which has been expanded in recent years to intersect with medical cannabis data.¹²
Crucially, the Board lacks independent statutory power to reschedule substances in Chapter 34-20B. Its role becomes operative only after the Legislature or DOH acts. If medical marijuana were moved to a lower state schedule (or if additional pharmacy-dispensing pathways were authorized), the Board would then update administrative rules governing pharmacist involvement, recordkeeping, labeling, and compliance with federal DEA registration requirements for Schedule III substances.¹³
Recent Board meeting materials (April 10, 2026) reflect this implementational focus: emphasis on controlled-substance inventories, DEA audits, inspection readiness, and rule packages, without direct discussion of marijuana rescheduling as a Board-initiated matter.¹⁴
III. Response to the April 2026 Federal Partial Shift
The federal action created a bifurcated posture: state-licensed medical marijuana now enjoys Schedule III treatment for purposes of research, § 280E tax relief, banking access, and DEA registration pathways.¹⁵ South Dakota’s medical program qualifies, yet Chapter 34-20B continues to list marijuana derivatives in Schedule I absent legislative amendment.¹⁶
SD House Bill 1016 (2026), enacted with emergency status, modifies provisions related to the controlled substances schedule.¹⁷ This demonstrates that South Dakota can move with relative speed on targeted updates when needed, even while preserving its deliberate statutory process. The Board will play a supporting role in any resulting pharmacy-rule adjustments.
This layered approach mirrors the Arizona-style conformity challenge described in contemporaneous analysis.¹⁸
IV. Practical and Policy Implications
The Board’s secondary role preserves legislative primacy on scheduling while ensuring professional oversight of any pharmacy-related implementation. In the post-April 2026 environment, this means:
• Medical cannabis establishments under Chapter 34-20G continue operating largely outside traditional pharmacy channels.
• Any expansion of pharmacist or pharmacy involvement in Schedule III marijuana products would require Board rulemaking to address dispensing, inventory, PDMP reporting, and federal compliance.
• The structure supports targeted accommodation rather than wholesale rescheduling, consistent with South Dakota’s historical caution toward treating marijuana as a prescription drug.¹⁹
For policymakers, the South Dakota model underscores that federal partial rescheduling does not compel immediate state schedule conformity. Instead, it invites careful calibration among DOH administration of the medical program, legislative schedule updates, and Board implementation of pharmacy rules.
Conclusion
The South Dakota Board of Pharmacy serves as guardian of pharmacy standards and controlled-substance handling rather than as the architect of scheduling policy. In the wake of the April 2026 federal partial Schedule III shift, its role will likely remain implementational—updating rules, guiding inspections, and ensuring compliance once the Legislature and DOH address broader conformity questions. This division of authority, embedded in the state’s dual-chapter framework, positions South Dakota to adapt deliberately to the new federal bifurcation while maintaining its distinct medical cannabis regime.
As other states confront similar pressures, South Dakota’s experience offers a clear illustration of how a traditional Board of Pharmacy can support, without driving, the regulatory response to federal change.²⁰
Footnotes
¹ Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License, 91 Fed. Reg. ___, at 22717 (Apr. 28, 2026).
² S.D. Codified Laws §§ 34-20B-1 to -41 (2026); S.D. Codified Laws §§ 34-20G-1 to -93 (2026).
³ S.D. Codified Laws § 34-20B-11 (criteria and DOH recommendation process).
⁴ Id.
⁵ S.D. Codified Laws § 34-20B-14(20) (tetrahydrocannabinol listing).
⁶ S.D. Codified Laws ch. 34-20G.
⁷ Press Release, U.S. Dep’t of Justice, Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-Issued License in Schedule III (Apr. 24, 2026).
⁸ S.D. Codified Laws ch. 36-11; S.D. Admin. R. 20:51 et seq.
⁹ S.D. Bd. of Pharmacy, Meeting Handouts (Apr. 10, 2026).
¹⁰ 2026 S.D. Sess. Laws ch. ___ (H.B. 1016) (modifying controlled substances schedule provisions; emergency declaration).
¹¹ S.D. Codified Laws § 34-20B-41 (Board rulemaking authority for administration).
¹² Federal Register notice, supra note 1, at 22719 (discussing state licensing regimes).
¹³ S.D. Codified Laws §§ 36-11-64 to -65 (inspection and enforcement powers).
¹⁴ Supra note 9.
¹⁵ Federal Register notice, supra note 1, at 22717–19.
¹⁶ S.D. Codified Laws § 34-20B-14(20).
¹⁷ Supra note 10.
¹⁸ Massachusetts and Arizona After the Partial Federal Schedule III Shift: Two Mature Markets, Two Different Conformity Problems, WeedPress (May 4, 2026), https://weedpress.org/2026/05/04/massachusetts-and-arizona-after-the-partial-federal-schedule-iii-shift-two-mature-markets-two-different-conformity-problems/.
¹⁹ See On the Reclassification of Marijuana, S.D. Republican Party (Jan. 1, 2026) (noting marijuana is not treated as a prescription drug under current state framework).
²⁰ Supra note 18.
WeedPress: The Paper Trail 
Leave a comment